Physician profile
Janani Sadasivan
NPI 1326609215
$3,756.13
in general payments reported to CMS, 2019-2025
27 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,129 · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,756.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.15 | 2024-2025 | |
| Inspire Medical Systems, INC. | $521.34 | 2024-2025 | Inspire |
| Ucb, INC. | $519.70 | 2024-2025 | Fintepla, Rystiggo, Briviact |
| Lundbeck LLC | $310.66 | 2024-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $275.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.38 | 2024-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $151.06 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $93.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $84.14 | 2025 | Wainua |
| Pfizer INC. | $71.44 | 2025 | |
| Jazz Pharmaceuticals INC. | $67.53 | 2024-2025 | |
| Amgen INC. | $54.67 | 2024-2025 | Uplizna |
| Argenx US, INC. | $53.49 | 2024-2025 | Vyvgart Hytrulo |
| C2n Diagnostics, LLC | $53.06 | 2025 | Precivityad2 |
| Novartis Pharmaceuticals Corporation | $49.75 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $46.31 | 2025 | Valtoco |
| Acadia Pharmaceuticals INC | $36.72 | 2024-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $34.59 | 2024 | Ingrezza |
| Amneal Pharmaceuticals LLC | $27.15 | 2025 | Crexont |
| Emd Serono, INC. | $26.80 | 2025 | |
| Boston Scientific Corporation | $26.49 | 2025 | General - Pain Management |
| Alexion Pharmaceuticals, INC. | $26.36 | 2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $25.17 | 2025 | Acthar |
| Lilly USA, LLC | $23.09 | 2024 | Emgality, Reyvow |
| Csl Behring | $22.62 | 2025 | Hizentra |
| Axsome Therapeutics, INC. | $19.79 | 2025 | Symbravo |
| Livanova USA, INC. | $18.72 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janani Sadasivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.